Dimension Therapeutics, Inc. Research and Development Expense
Dimension Therapeutics, Inc. reported Research and Development Expense of $16.13 million for the 3-month period ending 2017-09-30, per its 10-Q filed 2017-11-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2017-11-06
- Dimension Therapeutics, Inc. research and development expense for the quarter ending 2017-09-30 was $16.13M, a 16.94% increase year-over-year.
- Dimension Therapeutics, Inc. research and development expense for the quarter ending 2017-06-30 was $14.09M, a 25.35% increase year-over-year.
- Dimension Therapeutics, Inc. research and development expense for the quarter ending 2017-03-31 was $13.71M, a 55.75% increase year-over-year.
- Dimension Therapeutics, Inc. research and development expense for the quarter ending 2016-12-31 was $13.90M, a 58.78% increase year-over-year.
- Dimension Therapeutics, Inc. research and development expense for fiscal 2016 was $47.74M, a 40.45% increase from fiscal 2015.
- Dimension Therapeutics, Inc. research and development expense for fiscal 2015 was $33.99M, a 162.00% increase from fiscal 2014.
- Dimension Therapeutics, Inc. research and development expense for fiscal 2014 was $12.97M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2017-09-30 | $16.13M 10-Q · filed 2017-11-06 | $30.22M derived: sum of 2 quarters · filed 2017-11-06 | $43.94M 10-Q · filed 2017-11-06 | $57.84M derived: sum of 4 quarters · filed 2017-11-06 |
| 2017-06-30 | $14.09M 10-Q · filed 2017-08-08 | $27.80M 10-Q · filed 2017-08-08 | $41.70M derived: sum of 3 quarters · filed 2017-08-08 | $55.50M derived: sum of 4 quarters · filed 2017-11-06 |
| 2017-03-31 | $13.71M 10-Q · filed 2017-05-10 | $27.61M derived: sum of 2 quarters · filed 2017-05-10 | $41.41M derived: sum of 3 quarters · filed 2017-11-06 | $52.65M derived: sum of 4 quarters · filed 2017-11-06 |
| 2016-12-31 | $13.90M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $27.70M derived: sum of 2 quarters · filed 2017-11-06 | $38.94M derived: sum of 3 quarters · filed 2017-11-06 | $47.74M 10-K · filed 2017-03-09 |
| 2016-09-30 | $13.80M 10-Q · filed 2017-11-06 | $25.04M derived: sum of 2 quarters · filed 2017-11-06 | $33.84M 10-Q · filed 2017-11-06 | $42.59M derived: sum of 4 quarters · filed 2017-11-06 |
| 2016-06-30 | $11.24M 10-Q · filed 2017-08-08 | $20.05M 10-Q · filed 2017-08-08 | $28.80M derived: sum of 3 quarters · filed 2017-08-08 | $39.17M derived: sum of 4 quarters · filed 2017-08-08 |
| 2016-03-31 | $8.80M 10-Q · filed 2017-05-10 | $17.56M derived: sum of 2 quarters · filed 2017-05-10 | $27.93M derived: sum of 3 quarters · filed 2017-05-10 | $37.29M derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | $8.75M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $19.13M derived: sum of 2 quarters · filed 2017-03-09 | $28.48M derived: sum of 3 quarters · filed 2017-03-09 | $33.99M 10-K · filed 2017-03-09 |
| 2015-09-30 | $10.37M 10-Q · filed 2016-11-10 | $19.73M derived: sum of 2 quarters · filed 2016-11-10 | $25.24M 10-Q · filed 2016-11-10 | $30.05M derived: sum of 4 quarters · filed 2017-03-09 |
| 2015-06-30 | $9.36M 10-Q · filed 2016-08-11 | $14.87M 10-Q · filed 2016-08-11 | $19.68M derived: sum of 3 quarters · filed 2017-03-09 | $22.90M derived: sum of 4 quarters · filed 2017-03-09 |
| 2015-03-31 | $5.51M 10-Q · filed 2016-05-12 | $10.32M derived: sum of 2 quarters · filed 2017-03-09 | $13.54M derived: sum of 3 quarters · filed 2017-03-09 | |
| 2014-12-31 | $4.82M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $8.03M derived: sum of 2 quarters · filed 2017-03-09 | $12.97M 10-K · filed 2017-03-09 | |
| 2014-09-30 | $3.22M 10-Q · filed 2015-12-04 | $8.16M 10-Q · filed 2015-12-04 | ||
| 2013-12-31 | $2.81M 10-K · filed 2016-03-24 |